Sangamo Therapeutics Inc. (SGMO) - Projected Sales Volume

Official company branding of Sangamo Therapeutics, Inc. (SGMO)

Sangamo Therapeutics (SGMO) management is currently restructuring its business model due to a lack of funds, seeking to monetize its technologies through partnerships. The company plans to capture the DNA market by licensing its developments to pharma behemoths. After evaluating the projected revenue from sales on GURU.Markets, we find that the metric level is 0.04. This confirms the potential of the unique "zinc finger" system, which allows for the precise correction of genetic defects in human organs.

SGMO - Sangamo Therapeutics Company Expected Sales Volume over the range 07/04/2022 - 05/09/2026

Analytical breakdowns for Sangamo Therapeutics

- current price and projected stock value:
Fundamental company valuation:Sangamo BioSciences
Brand item of Sangamo

Assessing the margin of safety for Sangamo Therapeutics (SGMO) requires an analysis of projected revenue, calculated by benchmarking current growth rates against historical data to identify long-term trends. The expected sales trajectory for Sangamo Therapeutics (SGMO) on this chart reflects the commercialization potential of gene therapy, where financial success depends not on market cycles, but on clinical trial results and the terms of strategic partnerships.

Competitors of Sangamo Therapeutics (SGMO)

Company Future Sales Volume TEM (Tempus AI)|Company Future Sales Qiagen Group|Company Projected Revenue Ionis Pharma IONS|RGEN - Company Future Sales Volume|RNA - Company Projected Revenue|Company Future Revenue CRSP (CRISPR Therapeutics AG)|Sema4 (WGS) - Company Projected Revenue|Company Expected Revenue RARE (Ultragenyx)|Company Future Sales Volume BEAM|Projected Sales Volume Sarepta Corp|Company Projected Revenue Twist Bioscience, Inc. (TWST)|Company Future Sales Volume 10x Genomics TXG|Company Projected Revenue Intellia Therapeutics NTLA|Company Projected Revenue Volume STOK (Stoke Therapeutics, Inc.)|BLFS - Company Projected Revenue|Company Expected Sales Volume Wave Pharma|mazetx.com (MAZE) - Company Projected Revenue|SION - Company Future Sales|PRME (Prime Medicine Inc) - Projected Sales Volume|Taysha Gene Therapies, Inc. - Company Expected Revenue|Projected Sales Volume QURE|MGTX: Company Expected Revenue|Company Projected Revenue REGENXBIO RGNX|SLDB: Company Revenue Forecast|OCGN: Company Future Sales Volume|PACB - Projected Sales Volume|BNTC (Benitec Corp) - Company Future Sales Volume|Company Sales Forecast Design Corp DSGN|Company Projected Revenue Rocket Pharmaceuticals|Projected Sales Volume 4D Molecular Therapeutics, Inc.|Company Projected Revenue Lexeo (LXEO)|KRRO (Korro Bio Inc.) - Company Future Revenue|Projected Sales Volume EDIT (Editas Medicine, Inc.)|Projected Sales Volume Silence Therapeutics Corp SLN|PRQR - Company Projected Revenue|Company Future Sales Codexis Inc CDXS|NAUT: Projected Sales Volume|Company Revenue Forecast MGX|DTIL (precisionbiosciences.com) - Projected Sales Volume|Company Revenue Forecast GBIO (Generation Bio Co.)|Company Projected Revenue Boundless Bio (BOLD)|Exicure - Company Revenue Forecast|Projected Sales Volume IMNN (imunon.com)|Company Future Sales Phio Pharmaceuticals (PHIO)|MBIO: Company Future Sales Volume|Company Future Revenue RNAZ (transcodetherapeutics.com)|Bionano Genomics, Inc. (BNGO) - Company Projected Revenue|APDN - Company Future Sales|Company Future Sales Volume BLUE|Projected Sales Volume immunoprecise.com|Projected Sales Volume OMGA|Company Future Sales Singular Genomics Corp|Regulus Therapeutics - Company Future Sales Volume|SYRS (Syros Pharmaceuticals) - Company Expected Revenue|Telesis Bio Inc. - Projected Sales Volume|Company Future Revenue TCON (TRACON Pharmaceuticals Inc.)|UBX: Projected Sales Volume